We present a protocol describing a semi-quantitative method for measuring both, the attachment of influenza A virus to A549 cells, as well as the internalization of virus particles into the target cells by flow cytometry.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
We present a protocol describing a semi-quantitative method for measuring both, the attachment of influenza A virus to A549 cells, as well as the internalization of virus particles into the target cells by flow cytometry.
Attachment to target cells followed by internalization are the very first steps of the life cycle of influenza A virus (IAV). We provide here a detailed protocol for measuring relative changes in the amount of viral particles that attach to A549 cells, a human lung epithelial cell line, as well as in the amount of particles that are internalized into the cell. We use biotinylated virus which can be easily detected following staining with Cy3-labeled streptavidin (STV-Cy3). We describe the growth, purification and biotinylation of A/WSN/33, a widely used IAV laboratory strain. Cold-bound biotinylated IAV particles on A549 cells are stained with STV-Cy3 and measured using flow cytometry. To investigate uptake of viral particles, cold-bound virus is allowed to internalize at 37 °C. In order to differentiate between external and internalized viral particles, a blocking step is applied: Free binding spots on the biotin of attached virus on the cell surface are bound by unlabeled streptavidin (STV). Subsequent cell permeabilization and staining with STV-Cy3 then enables detection of internalized viral particles. We present a calculation to determine the relative amount of internalized virus. This assay is suitable to measure effects of drug-treatments or other manipulations on attachment or internalization of IAV.
The entry of influenza A virus (IAV) is a multi-step process that starts with the binding of the virus to receptors on the plasma membrane of target cells 1. The receptor for IAV is sialic acid which is present on a large variety of glycoproteins and glycolipids. The hemagglutinin (HA) protein of IAV which is present in the viral envelope binds to sialic acid and thereby mediates attachment of the viral particles to the plasma membrane of target cells 2. The virus enters the cells via clathrin-mediated endocytosis but also alternative entry pathways, such as macropinocytosis, have been described 3-6. The interaction between HA and sial....
Access restricted. Please log in or start a trial to view this content.
Note before start: Use laminar flow hood and appropriate biocontainment when working with live virus. Here, we describe growth conditions suitable to culture influenza virus strain A/WSN/33. Multiplicity of infection (MOI) and incubation times may vary depending on virus strain used.
1. Preparation of Biotinylated A/WSN/33 Virus
Access restricted. Please log in or start a trial to view this content.
A cartoon describing the four different experimental conditions is shown in Figure 1. Results of a representative experiment are presented in Figures 2-5. In the “0 min” sample, biotinylated virus is cold-bound to target cells which can be visualized by STV-Cy3 staining (Figures 1 and 2). When a blocking step (in the “0 min + STV” sample) is applied, virus at the cell surface can no longer be detected by STV-Cy3 staining. As a result, th.......
Access restricted. Please log in or start a trial to view this content.
Our protocol describes an easy way of measuring virus attachment and internalization by flow cytometry. It allows the use of labeled wildtype virus which mimics more closely virus infections compared to the use of virus-like particles (VLP). While our protocol has been optimized to measure attachment and internalization of IAV it can easily be adapted for other viruses. In addition, as flow cytometry is used for readout, co-stainings can be easily added to the protocol e.g. to test expression levels following kn.......
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
This work was supported by a grant from the Swiss National Science Foundation (31003A_135278) to SSt. MOP is the beneficiary of a doctoral grant from the AXA Research Fund. We thank Patricia Nigg for help with the design of Figure 1.
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| DMEM | Life Technologies | 41966-052 | |
| FBS | Life Technologies | 10270-106 | |
| Penicillin-Streptomycin | Life Technologies | 15140-163 | |
| PBS | Life Technologies | 14190-169 | |
| BSA | VWR Calbiochem | 126579 | |
| HEPES | Life Technologies | 15630-100 | |
| D-Sucrose | Fluka | 84100 | |
| TRIS | Biosolve BV | 20092391 | |
| EDTA | Sigma-Aldrich | 3680 | |
| EZ-LINK NHS-SS-BIOTIN kit | Fisher Scientific | W9971E | |
| Bio Rad Protein Bio Assay | Bio Rad | 500-0006 | |
| deepwell tubes (1.2 ml microtubes) | Milian | 82 00 001 | |
| PFA | Lucerna chem Electron microscopy sciences | 15710 | |
| ultracentrifuge tubes | Hemotec HmbH | 253070 | |
| Triton X-100 | Fluka | 93420 | |
| STV-Cy3 | Life Technologies | 43-4315 | |
| STV | Life Technologies | 43-4302 | |
| sodium azide | Fluka | 71290 | |
| bacterial neuraminidase/sialidase | Sigma-Aldrich | N6514-1UN |
Access restricted. Please log in or start a trial to view this content.